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Abstract
Background: Drug resistance is a growing challenge to tuberculosis (TB) control worldwide, but particularly salient
to countries such as Myanmar, where the health system is fragmented across the public and private sector. A recent
systematic review has identified a critical lack of evidence for local policymaking, particularly in relation to drivers of
drug-resistance that could be the target of preventative efforts. To address this gap from a health systems perspective,
our study investigates the healthcare-seeking behavior and preferences of recently diagnosed patients with
drug-resistant tuberculosis (DR-TB), focusing on the use of private versus public healthcare providers.
Methods: The study was conducted in ten townships across Yangon with high DR-TB burden. Patients newly-diagnosed
with DR-TB by GeneXpert were enrolled, and data on healthcare-seeking behavior and socio-economic characteristics
were collected from patient records and interviews. A descriptive analysis of healthcare-seeking behavior was followed
by the investigation of relationships between socio-economic factors and type of provider visited upon first feeling
unwell, through univariate logistic regressions.
Results: Of 202 participants, only 8% reported first seeking care at public facilities, while 88% reported seeking care at
private facilities upon first feeling unwell. Participants aged 25–34 (Odds Ratio = 0.33 [0.12–0.95]) and males
(Odds Ratio = 0.39 [0.20–0.75]) were less likely to visit a private clinic or hospital than those aged 18–24 and
females, respectively. In contrast, participants with higher income were more likely to utilize private providers.
Prior to DR-TB diagnosis, 86% of participants took medications from private providers. After DR-TB diagnosis,
only 7% of participants continued to take medications from private providers.
Conclusion: In urban Myanmar, most patients shifted to being managed exclusively in the public sector after
being formally diagnosed with DR-TB. However, since the vast majority of DR-TB patients first visited private
providers in the period leading to diagnosis, related issues such as unregulated quality of care, potential delays
to diagnosis, and lack of care continuity may greatly influence the emergence of drug-resistance. A greater
understanding of the health system and these healthcare-seeking behaviors may simultaneously strengthen TB
control programmes and reduce government and out-of-pocket expenditures on the management of DR-TB.
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Background
Although tuberculosis (TB) mortality has fallen by 47%
between 1990 and 2015, TB remains one of the world’s
deadliest infectious diseases. In 2016 there were still ap-
proximately 1.3 million deaths due to TB (among HIV-
negative), surpassing an estimated 1.0 million due to
HIV / AIDS. Moreover, in recent years, public health
experts have become increasingly concerned about the
emergence and spread of drug-resistant strains of TB,
particularly those that are not controlled by one or both
most effective anti-TB drugs, rifampicin and isoniazid
(referred to as DR-TB going forward). Growing drug-
resistance is a major hurdle to global TB control, threat-
ening to stall or even reverse the declines in TB inci-
dence and mortality [1].
Recent WHO figures indicate that 19% of previously-
treated TB cases and 4.1% of new TB cases globally were
DR-TB. This burden is unequally distributed, both
spatially and economically: of the 600,000 DR-TB cases
emerging in 2016, 91% originated in just 30 countries, 22
of which are classified as low or lower-middle income [2].
In most of these countries, government spending on
health per capita is relatively low, and out-of-pocket ex-
penditures exceed 15% of total healthcare costs (well over
the suggested benchmark threshold for universal health
coverage) [1, 3]. These and other systemic barriers - such
as high costs of formal diagnosis and treatment; limited
accessibility; poor management and infrastructure; and
weak regulatory oversight - result in health systems that
are already overstrained yet faced with a growing and in-
creasingly complex burden of diseases, creating ideal con-
ditions for the continued rise of drug-resistance [4]. In
addition to these macro-level factors, however, the role of
patients and their behavior is also critical. Individual be-
liefs and preferences, as well as household social and fi-
nancial constraints, can lead to suboptimal risk-taking,
healthcare-seeking and compliance-related behaviors, the
consequences of which may be further exacerbated by
weaknesses in the underlying health system; for instance,
poor health literacy coupled with limited access and high
prices can lead to delays in diagnosis and treatment [5–7].
Alternatively, lack of patient motivation to comply with
treatment, combined with low levels of monitoring will
lead to treatment failure and contribute to the emergence
of DR-TB [8, 9].
Myanmar exemplifies the case of a lower-income
country with a high DR-TB burden. The TB incidence
rate is 361 per 100,000 population, approximately 2.5
times higher than the global average. DR-TB incidence is
approximately 13,000 per year, placing Myanmar among
the highest DR-TB burden countries in the world. Over-
all, 27% of previously treated TB cases and 5.1% of new
TB cases were estimated to be DR-TB, higher than both
the global and regional average [1]. Despite progress
towards eliminating infectious diseases per the “Good
Health and Wellbeing” portion of the Sustainable Devel-
opment Goals, Myanmar’s health system is still develop-
ing. Although international attention and funding has
turned towards Myanmar in recent years, low levels of
human capital and government spending in healthcare (3.
4% of general government spending in 2014–2015) [10]
continue to constrain access, coverage and service quality.
A recent systematic review in Myanmar identified a crit-
ical lack of evidence on TB in the local context to inform
policy decisions. Specifically, the study highlighted a need
for funders and policymakers to have better information
about drivers of drug-resistance that could be the target of
preventative efforts and health systems strengthening [11].
To address this gap, our present study investigates the
healthcare-seeking behavior and preferences of recently
diagnosed DR-TB patients.
Methods
Study setting
Myanmar is a lower-middle income country with a
population of 53 million as of 2016. It is bordered by
China, India, Bangladesh, Thailand, and Laos. Healthcare
services in Myanmar are provided by both the private
and public sector. The public health sector is overseen
by the Ministry of Health and Sports, which manages
public services such as those provided by the National
TB Programme (NTP). TB control activities are imple-
mented through Yangon’s Township Health Departments
(THDs), which are the main health facilities providing
primary healthcare, including TB diagnosis, case regis-
tration, and treatment provision. Private sector providers
include hospitals, pharmacies, small clinics, and informal
drug sellers and dispensaries, some of which are not for-
mally registered or regularly monitored. Many private
healthcare providers or organizations that work in part-
nership with the government– such as the Myanmar
Medical Association (MMA) and Population Service
International (PSI) – are regulated and work closely with
the NTP to provide standardized treatment [12]. This
cross-sectional study was conducted in ten THDs across
Yangon, identified by the NTP as having a high DR-TB
burden.
Participants
Our study enrolled all newly-diagnosed adult pulmonary
DR-TB patients with confirmed rifampicin resistance
based on GeneXpert results at the THDs. Recruitment
was conducted over a six-month period from September
2014 to March 2015. The exclusion criteria were: age <
18 years; known pregnancy at time of data collection;
residence outside Yangon or in Yangon < 3 months; and
extra-pulmonary TB only.
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Data collection
After verifying eligibility and willingness to participate
(through written consent), we retrospectively collected
data from DR-TB patients 3 months after diagnosis at
THDs. All DR-TB patients had previously been treated
for TB. Data were collected by administering a pre-
piloted, structured questionnaire at the participant’s
home, collecting data about participant’s socio-economic
status, symptoms, treatment adherence, healthcare-
seeking behavior, and treatment support. Questions
about healthcare-seeking behavior focused on decisions
made when patients had a typical mild or moderate ill-
ness (such as a cough) and not specifically for their re-
cent TB symptoms; this allowed data collection on
healthcare-seeking before patients may have been aware
that they had TB. A local data collector fluent in the na-
tive language was trained to administer the question-
naires and assigned to each township.
Data management
Data collected on paper records was manually checked at
the local study site for accuracy by the study supervisor.
Data were then entered into Epidata (Version 3.1, The
EpiData Association, Odense, Denmark) and checked for
quality through blinded double entry and restricting out-
of-range values. The raw data was then transferred to
Stata (version 10, Stat Corporation, College Station, TX)
for management and statistical analysis.
Statistical analysis
We conducted a descriptive analysis, reporting numbers,
percentages, and 95% confidence intervals (of the pro-
portion) for categorical variables summarizing individual
and household socio-economic characteristics, as well as
key healthcare seeking behaviors. We then investigated
the relationship between patients’ socio-economic fac-
tors and healthcare seeking behavior in terms of visits to
a private provider when initially feeling unwell. Specific-
ally, the outcome variable was whether study partici-
pants self-reported that they usually visit a private clinic
or hospital upon first feeling unwell (with any ailment).
Univariate logistic regressions were conducted, and re-
sults were stated in terms of odds ratios and 95% confi-
dence intervals.
Results
Over the study period, 205 eligible participants with DR-
TB were diagnosed at the ten THDs. Three refused to
participate, resulting in 202 DR-TB participants being in-
cluded in the final analysis. Demographic and socio-
economic characteristics of the study participants are
summarized in Table 1. Approximately 70% of the par-
ticipants are aged between 25 and 54, representing the
most active socio-economic group, and the number of
Table 1 Demographic and socio-economic characteristics of
DR-TB participants (N = 202)
Characteristics N (%) 95% CI
Age
18–24 26 (13%) (9–18%)
25–34 57 (28%) (22–35%)
35–44 43 (21%) (16–28%)
45–54 38 (19%) (14–25%)
55–64 22 (11%) (7–16%)
65> 16 (8%) (5–13%)
Female 64 (32%) (26–39%)
Ethnic group
Bamar 169 (84%) (78–88%)
Mixed 6 (3%) (1–7%)
Ethnic minority 27 (13%) (9–19%)
Religion
Buddhist 185 (92%) (87–95%)
Christian 10 (5%) (3–9%)
Muslim 7 (4%) (2–7%)
Marital status
Single never married 61 (30%) (24–37%)
Married / cohabitating 121 (60%) (53–67%)
Divorced / separated / widowed 20 (10%) (7–15%)
Occupation
Dependent on earnings of a family member 44 (22%) (17–28%)
Daily wage earner 5 (3%) (1–6%)
Self-employed or private employee 61 (30%) (24–37%)
Government employee 13 (6%) (4–11%)
Unemployed 71 (35%) (29–42%)
Retired or other 8 (4%) (2–8%)
Education level
None or less than primary 35 (17%) (13–23%)
Primary school completed 54 (27%) (21–33%)
Middle school completed 59 (29%) (23–36%)
High school completed or graduated 54 (27%) (21–33%)
Household income in kyat (and USD)a
0/100000 (0/91) 38 (19%) (14–25%)
100,001/150000 (91/136) 38 (19%) (14–25%)
150,001/200000 (136/18) 46 (23%) (18–30%)
200,001/300000 (181/271) 40 (20%) (15–26%)
300,001/max (271/max) 33 (16%) (12–22%)
Missing 7 (4%) (2–7%)
Type of dwelling
Permanent 119 (59%) (52–66%)
Informal 83 (41%) (35–48%)
Patient still alive
Yes 190 (94%) (90–97%)
No 12 (6%) (3–10%)
a1 USD = 1105 Kyat on 15 June 2015 (Source: Central Bank of Myanmar [30])
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males was roughly double that of females. Although 12
participants died before the interview, they remained in
our analysis to avoid bias from removing this subset, and
information about healthcare-seeking behavior was col-
lected from their family members.
As expected, most participants are of the Bamar ethnic
group (84%), the dominant ethnic group in Myanmar,
and are Buddhist (92%), the dominant religion in the
country. Of the 202 participants, 41% reported living in
informal housing (without official address and usually
built of impermanent materials rather than permanent
structures).
Table 2 shows the healthcare-seeking behavior of DR-
TB participants in our study. Only 8% of study partici-
pants reported a preference to seek care at public facil-
ities upon first feeling unwell (with any ailment). Most
participants utilized the private sector, with 62% visiting
private clinics and hospitals, and 26% visiting private
pharmacies or drug sellers. A small number (3%) went
to informal drug sellers or traditional healers. For
healthcare-seeking behavior in the past 2 years, 72% re-
ported having seen a private doctor, while use of trad-
itional healers was low (7%). Before diagnosis of DR-TB
was confirmed at a THD, most participants used medi-
cations from a private doctor or pharmacy (86%).
Following the diagnosis of DR-TB – at approved govern-
ment facilities (i.e. NTP or the public sector) – only 34
(17%) participants still visited private doctors and only 8
out of 34 participants (24%) took treatment from them.
When considering the full range of private providers
(not only private doctors, but including pharmacies and
traditional healers as well), 15 (7%) participants reported
taking any treatment from these providers following
diagnosis.
Table 3 shows the results of univariate logistic regres-
sion with the outcome being whether participants re-
ported first seeking care at a private clinic or hospital
when they are unwell. Participants aged 25–34 (OR: 0.33
[0.12–0.95]) were significantly less likely to go to a pri-
vate clinic or hospital than those aged between 18 and
24. Male participants (OR: 0.39 [0.20–0.75]) were also
less likely to go to a private clinic or hospital compared
to female participants. Participants with greater income
had higher odds of visiting private providers, in particu-
lar those with incomes above 300,000 Kyat (OR: 5.040
[1.60–15.84]).
Discussion
Drug-resistant TB is a challenge for resource-constrained
settings where healthcare is provided by a range of health-
care providers in the public and private sectors. In coun-
tries such as Myanmar, in addition to low government
funding [10], fragmented healthcare systems may contrib-
ute to the emergence of drug-resistance and reduce
capacity to manage and diagnose drug-resistant cases
[13–15]. To our knowledge, ours is the first study to
quantitatively evaluate the health-seeking behavior of DR-
TB patients in Myanmar, focusing on behavior with re-
spect to the use of private healthcare providers.
We found that the vast majority of participants prefer
to utilize the private sector and take prescribed medica-
tions from private providers when they start feeling un-
well. Similar findings are reported in other Southeast
and South Asian countries with dominant private sectors
[16, 17]. It is important to highlight the heterogeneity of
the provider landscape for allopathic health services in
Myanmar and other regional countries; the private
Table 2 Healthcare-seeking behavior of DR-TB participants
(N = 202)
Healthcare-seeking behavior N (%) 95% Confidence
Interval (of the
proportion)
Type of health care provider visited when first feeling unwell
Private clinic/hospital 126 (62%) (55–69%)
Public clinic/hospital 16 (8%) (5–13%)
Pharmacy (formal) 53 (26%) (21–33%)
Informal drug stores 3 (2%) (1–5%)
Informal non-medical provider/
traditional healer
1 (1%) (1–4%)
Nobody 3 (2%) (1–5%)
Visited private doctor in the past 2 years?
No 56 (28%) (22–34%)
Yes 146 (72%) (66–78%)
Visited traditional healer in the past 2 years?
No 188 (93%) (89–96%)
Yes 14 (7%) (4–11%)
Taken any medication from private/pharma before DR-TB diagnosis?
No 29 (14%) (10–20%)
Yes 173 (86%) (80–90%)
Visited private doctor for DR-TB concerns since diagnosis?
No 168 (83%) (77–88%)
Yes 34 (17%) (12–23%)
Taken any treatment for DR-TB from private doctor or pharmacy since
diagnosis?
No 194 (96%) (92–98%)
Yes 8 (4%) (2–8%)
Taken any treatment for DR-TB from traditional healer since diagnosis?
No 194 (96%) (92–98%)
Yes 8 (4%) (2–8%)
Taken any treatment for DR-TB in private sector (private doctor,
pharmacy, traditional healer) since diagnosis?
No 187 (93%) (88–95%)
Yes 15 (7%) (5–12%)
Sidharta et al. BMC Health Services Research  (2018) 18:276 Page 4 of 7
healthcare sector includes independently operating, usu-
ally unregulated GPs, pharmacies, and hospitals as well
as international and local non-government organizations
(NGOs) such as Population Services International (PSI).
Private GPs also undertake dual practice which means
that they are employed in public sector and see private
patients outside of office hours as well [18]. Thus, the
diverse entities that constitute the private sector add to
its complexity. In contrast to the high use of allopathic
private providers, we found limited use of traditional or
complementary medicine practitioners in Yangon. Fi-
nally, regardless of which provider in the private sector
participants initially choose, after a diagnosis of DR-TB
in the public health sector, we found that the majority
switch to using the public sector and do not continue to
be treated by private healthcare providers.
A highly-fragmented pathway to care with a large de-
facto role for the private sector, as found in our study,
can facilitate the development of DR-TB. The quality of
care received at unregulated private providers is poorly
studied or documented through the routine monitoring
systems that are applied in the public sector. There is
some evidence indicating that diagnosis and treatment
in the private sector can deviate from guidelines for ap-
propriate patient management [19] and that poor treat-
ment compliance in the private sector contributes to
drug-resistant TB [20–22]. We do not know the length
of delay to diagnosis of DR-TB in Myanmar; a long delay
to initiating treatment may result in spread of infection
and this should be monitored among newly diagnosed
DR-TB patients.
From the perspective of patient choice, use of the pri-
vate or public sector is determined by both push and
pull factors. Few studies in Myanmar have looked at the
motivations for initially using private as opposed to pub-
lic healthcare. One study found most people went to a
private GP nearby since it was more convenient and was
encouraged by former patients who had been cured of
the disease. Long waiting times and perceived prolonged
risk to exposure in the waiting rooms were also reported
as deterrents to the use of the public sector [18].
Table 3 Logistic regression on the type of healthcare provider
visited when first time feeling unwell (private clinic/hospital: yes,
others: no, N = 202)
Characteristics Yes No Odds
ratio
95% Confidence
interval
Age
18–24 20 6 1 1
25–34 30 27 0.33* (0.12,0.95)
35–44 28 15 0.56 (0.19,1.69)
45–54 25 13 0.58 (0.19,1.79)
55–64 11 11 0.30 (0.09,1.03)
65> 12 4 0.90 (0.21,3.85)
Sex
Woman 49 15 1 1
Man 77 61 0.39** (0.20,0.75)
Ethnic group
Bamar 106 63 1 1
Mixed 4 2 1.19 (0.21,6.68)
Ethnic minority 16 11 0.86 (0.38,1.98)
Religion
Buddhist 115 70 1 1
Christian 7 3 1.42 (0.36,5.67)
Muslim 4 3 0.81 (0.18,3.73)
Marital status
Single never married 42 19 1 1
Married/cohabitating 73 48 0.69 (0.36,1.32)
Divorced/separated/widowed 11 9 0.55 (0.20,1.56)
Occupation
Dependent on earnings of a
family member
36 8 1 1
Daily wage earner 4 1 0.89 (0.09,9.06)
Self-employed or private
employee
35 26 0.30* (0.12,0.75)
Government employee 7 6 0.26* (0.07,0.98)
Unemployed 40 31 0.29** (0.12,0.70)
Retired or other 4 4 0.22 (0.05,1.08)
Education level
None or Less than primary 20 15 1 1
Primary school completed 35 19 1.38 (0.58,3.30)
Middle school completed 34 25 1.02 (0.44,2.38)
High school completed or
graduated
37 17 1.63 (0.68,3.94)
Household incomed in kyat (and USD)a
0/100000 (0/91) 20 18 1 1
100,001/150000 (91/136) 20 18 1 (0.41,2.46)
150,001/200000 (136/181) 27 19 1.28 (0.54,3.04)
200,001/300000 (181/271) 25 15 1.50 (0.61,3.70)
300,001/max (271/max) 28 5 5.04** (1.60,15.84)
Table 3 Logistic regression on the type of healthcare provider
visited when first time feeling unwell (private clinic/hospital: yes,
others: no, N = 202) (Continued)
Characteristics Yes No Odds
ratio
95% Confidence
interval
Missing 6 1 5.40 (0.59,49.26)
Permanent/informal dwelling
Permanent 79 40 1 1
Informal 47 36 0.66 (0.37,1.18)
a1 USD = 1105 Kyat on 15 June 2015 (Source: Central Bank of Myanmar [30])
*: p < 0.05, **: p < 0.01
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In our study, we found that women were more likely to
use private providers, consistent with other research that
also found that male TB patients outnumbered females in
Yangon’s public health sector [23]. Evidence from other
settings indicates that women may experience greater
stigma from TB or challenges in travelling long distances
to reach healthcare, and private providers may be per-
ceived to allow greater patient privacy and be more con-
veniently located [24–26]. Further research is needed to
explain other demographic differences, such as age-related
disparities in seeking care from private providers.
The most likely main determinant of switching to the
public sector after diagnosis with DR-TB is the high cost
of future visits in the private sector, because DR-TB
requires expensive medication [27, 28]. A study in
Cambodia also found that patients would initially visit
private healthcare providers and switch to the public
sector once they knew they had TB, because they wanted
to access free TB treatment which would not be available
in the private sector [29]. Proximity and access to health
public facilities did not appear to be a major barrier in
our study in an urban setting, with 78% of the partici-
pants able to reach NTPs within 30 min.
A major strength of this study is the collection of data
via detailed, face-to-face interviews with all newly-
diagnosed DR-TB participants in the studied townships,
which has not previously been collected in Myanmar.
However, our study is limited in that we only focus on
selected townships within Yangon, and so our findings
could more representative of urban settings. For ex-
ample, the finding that few DR-TB patients used trad-
itional healers may differ in rural settings. Costs of
seeking care are also missing from our dataset as we did
not receive ethical approval to collect this information.
Likewise, our study lacks data on delays to diagnosis of
DR-TB, as well as the time period between first seeking
care in the private healthcare sector and shifting to the
public sector. Lastly, there is considerable diversity in
private sector providers that we have not investigated.
Differences in quality of care, referral practices and costs
may differ between registered/regulated private provider
and informal or untrained providers.
Conclusions
As funding increases for infectious disease control in
Myanmar, this research provides initial evidence for pol-
icy making and resource allocation decisions [10, 11].
Specifically, our study indicates that private allopathic
healthcare providers are the first point of contact when
patients are unwell, and they can therefore play a major
positive or negative role in healthcare provision in urban
settings. Investments that can improve the quality of
care, delays to diagnosis, and continuity of care within
the private sector, or coordination between the public
and private sector, have the potential to impact a large
proportion of patients and reduce the growth in drug-
resistance in Myanmar. The current study adds to the
limited evidence on healthcare-seeking behavior among
DR-TB patients in Asian settings with pluralistic health
systems. Future studies should examine what motivates
patients to use the private sector as the first point on
contact when ill, and subsequently understand the qual-
ity of care for different types of providers within this
sector. Longitudinal studies can help elucidate factors
associated with timing of diagnosis and treatment up-
take, and treatment adherence, which will support the
design and funding of effective interventions in the
future.
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